Comparison between admission natriuretic peptides, NGAL and sST2 testing for the prediction of worsening renal function in patients with acutely decompensated heart failure
Benedetta De Berardinis(Azienda Ospedaliera Sant'Andrea), from the Global Research on Acute C, Blair A. Parry(Massachusetts General Hospital), L. Magrini(Arcetri Astrophysical Observatory), Charles Coudriou(Assistance Publique – Hôpitaux de Paris), James L. Januzzi(Harvard University), Hanna K. Gaggin(Massachusetts General Hospital), Matthieu Legrand(University of California, San Francisco), Alexandra Femia(Harvard University), Malha Sadoune(Inserm), Mandy L. Simon(Harvard University), John T. Nagurney(Harvard University), Anju Bhardwaj(The University of Texas Health Science Center at Houston), Shweta R. Motiwala(Harvard University), Benedetta Zancla(Azienda Ospedaliera Sant'Andrea), Arianna M. Belcher(Harvard University), Salvatore Di Somma(Clinique Saint Pierre)
Cited by 33
Related Papers
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency department (PRIDE) study
|The American Journal of Cardiology|2005|1.2k
State of the Art: Using Natriuretic Peptide Levels in Clinical Practice
|European Journal of Heart Failure|2008|837
Clinical Picture and Risk Prediction of Short-Term Mortality in Cardiogenic Shock
|European Journal of Heart Failure|2015|792
Heart Failure Association of the European Society of Cardiology Practical Guidance on the Use of Natriuretic Peptide Concentrations
|European Journal of Heart Failure|2019|786